ReviewTherapeutic advances in medical oncology2026
Driving precision medicine in testicular germ cell tumors: from preclinical models to clinical applications.
Review in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testicular cancer is the most common cancer in young adult men, and its incidence is increasing globally, with testicular germ cell tumors (TGCT) being the most frequent subtype. These tumors show remarkable sensitivity to cisplatin, but there is a small subset of patients that develop resistance to the therapy, experiencing low quality of life and having no treatment options. Nowadays, there are a number of models that are useful for studying TGCT tumorigenesis and identifying novel targeted therapies for these patients. Thus, in this review, we aim to provide a comprehensive overview of the in vitro and in vivo TGCT models that are currently available, and also to summarize the main findings that have been made in the last years regarding preclinical and clinical studies of novel targeted therapies in TGCT patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.